ClinConnect ClinConnect Logo
Search / Trial NCT05201781

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Launched by JANSSEN RESEARCH & DEVELOPMENT, LLC · Jan 10, 2022

Trial Information

Current as of July 23, 2025

Recruiting

Keywords

ClinConnect Summary

This clinical trial is looking at the long-term effects of a treatment called ciltacabtagene autoleucel (often referred to as cilta-cel) in patients who have been previously treated for multiple myeloma, a type of blood cancer. The main goal is to gather information about any delayed side effects that might occur after receiving cilta-cel and to better understand how safe this treatment is over time.

To participate in this study, individuals must be between the ages of 65 and 74 and have already received at least one dose of cilta-cel in a previous clinical trial sponsored by the company. Participants will need to agree to be part of this new study by providing informed consent. Those who join can expect to share their health information and experiences related to the treatment, which will help researchers learn more about its long-term safety.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Participants who have received at least one dose of cilta-cel in a Company-sponsored clinical study
  • Participants who have provided informed consent for this study

About Janssen Research & Development, Llc

Janssen Research & Development, LLC, a subsidiary of Johnson & Johnson, is a leading pharmaceutical company dedicated to advancing innovative therapies in multiple therapeutic areas, including oncology, immunology, neuroscience, infectious diseases, and cardiovascular health. With a strong commitment to scientific excellence and patient-centered research, Janssen leverages cutting-edge technology and collaborative partnerships to drive the development of transformative treatments. The company is focused on addressing unmet medical needs through rigorous clinical trials and a robust pipeline, aiming to improve health outcomes and enhance the quality of life for patients worldwide.

Locations

Chicago, Illinois, United States

Boston, Massachusetts, United States

New York, New York, United States

Philadelphia, Pennsylvania, United States

San Francisco, California, United States

Chicago, Illinois, United States

Bronx, New York, United States

Buffalo, New York, United States

Detroit, Michigan, United States

Saint Louis, Missouri, United States

Boston, Massachusetts, United States

Boston, Massachusetts, United States

Hackensack, New Jersey, United States

New York, New York, United States

Nashville, Tennessee, United States

Duarte, California, United States

Boston, Massachusetts, United States

Tampa, Florida, United States

Groningen, , Netherlands

Tel Aviv, , Israel

Indianapolis, Indiana, United States

New Brunswick, New Jersey, United States

Houston, Texas, United States

San Francisco, California, United States

Stanford, California, United States

Gent, , Belgium

Boston, Massachusetts, United States

Atlanta, Georgia, United States

Paris, , France

Amsterdam, , Netherlands

Pittsburgh, Pennsylvania, United States

Leuven, , Belgium

Nanjing, , China

Salamanca, , Spain

Westwood, Kansas, United States

Charlotte, North Carolina, United States

Shibuya, , Japan

Rochester, Minnesota, United States

Shanghai, , China

Beijing, , China

Tel Aviv, , Israel

Nagoya, , Japan

Pamplona, , Spain

Shanghai, , China

Chengdu, , China

Hangzhou, , China

Phoenix, Arizona, United States

Milwaukee, Wisconsin, United States

Xi'an, , China

Ramat Gan, , Israel

Fuzhou, , China

Shanghai, , China

Nagoya, , Japan

Chengdu, , China

Shanghai, , China

Shanghai, , China

Salamanca, , Spain

Nord, , France

Patients applied

0 patients applied

Trial Officials

Janssen Research & Development, LLC Clinical Trial

Study Director

Janssen Research & Development, LLC

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials